RecruitingNot ApplicableNCT07059546

Hypersensitivity to Adrenomedullin in Post-Traumatic Headache

Hypersensitivity to Adrenomedullin in Post- Traumatic Headache: A Randomized Clinical Trial


Sponsor

Danish Headache Center

Enrollment

21 participants

Start Date

Aug 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Adrenomedullin is a neuropeptide implicated in the pathogenesis of headache. This study investigates whether adrenomedullin induces headache with migraine-like features in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Adrenomedullin and a drug called Placebo for people with posttraumatic headache. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAdrenomedullin

The participants will receive continuous intravenous infusion of 20 mL of 19.9 pmol/kg/min adrenomedullin over 20 minutes.

DRUGPlacebo

The participants will receive a continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.


Locations(1)

Rigshospitalet-Glostrup

Glostrup Municipality, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07059546


Related Trials